GSK Secures EU Approval for Nucala in COPD Treatment (LSE: GSK)

The European Commission approved GSK's (LSE: GSK) Nucala for long-term obstructive pulmonary disease treatment on February 7, 2026, expanding its authorization to include chronic obstructive pulmonary disease (COPD). The approval follows positive results from pivotal trials showing significant improvement in symptoms and reduced exacerbations. The decision is expected to strengthen GSK's position in the respiratory therapeutics segment and support growth in the coming quarters.